| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
Pulsatilloside E targets the nervous system, exhibiting neuroprotective effects. As a triterpenoidal saponin, it may interact with multiple cellular pathways involved in neuronal survival and function. Its mechanism of action likely involves modulation of signaling pathways that protect neurons from damage or degeneration. The compound's neuroprotective properties make it a subject of interest for research into neurodegenerative diseases.
|
|---|---|
| ln Vitro |
In vitro, Pulsatilloside E has been shown to possess neuroprotective effects. Its activity can be assessed by measuring its ability to protect neuronal cells from various insults, such as oxidative stress or excitotoxicity. The compound's efficacy in preventing neuronal cell death can be evaluated using cell viability assays in neuronal cell cultures. It is a triterpenoidal saponin isolated from the roots of Pulsatilla chinensis.
|
| ln Vivo |
In vivo, Pulsatilloside E has neuroprotective effects. It can be used in animal models of neurological disorders to study its potential therapeutic benefits. The compound's ability to protect against neuronal damage and improve functional outcomes can be assessed in vivo. However, specific in vivo study details are not extensively documented in general references.
|
| Enzyme Assay |
As a natural product, Pulsatilloside E is not typically subjected to standard enzyme or receptor binding assays. Its biological activity is assessed through cell-based and in vivo studies rather than through specific receptor binding assays. The compound's purity and identity are confirmed by analytical techniques such as HPLC and NMR spectroscopy. It is available as a high-purity reference standard for analytical and pharmacological experiments.
|
| Cell Assay |
Pulsatilloside E is used in cell-based assays to evaluate its neuroprotective effects. Neuronal cell lines or primary neurons are treated with the compound, and cell viability is measured under conditions of stress. The compound's ability to protect neurons from damage can be assessed by measuring markers of cell death, oxidative stress, and mitochondrial function. It is used for content determination and pharmacological experiments.
|
| Animal Protocol |
The in vivo effects of Pulsatilloside E can be studied in animal models of neurological disorders. The compound is administered to animals, and its neuroprotective effects are assessed by behavioral tests, histology, and biochemical analysis of brain tissue. However, specific animal study protocols are not detailed in general references. The compound is primarily used in research settings.
|
| ADME/Pharmacokinetics |
Pulsatilloside E has a molecular weight of 1383.52 g/mol and a molecular formula of C65H106O31. It is a 28-O-β-D-glucopyranosyl ester. The compound is typically stored under recommended conditions as specified in the Certificate of Analysis. It is soluble in DMSO and other organic solvents. As a high-molecular-weight saponin, its pharmacokinetic properties would be characteristic of this class of natural products.
|
| Toxicity/Toxicokinetics |
Toxicological data for Pulsatilloside E are not extensively detailed, as it is a research compound. It is not intended for human or veterinary use. Standard laboratory safety precautions, including the use of personal protective equipment (PPE), should be followed when handling the compound. Its safety profile would be established through dedicated toxicology studies if it were to be developed further.
|
| References | |
| Additional Infomation |
Lupinane extracted from the root of Pulsatilla chinensis (Ranunculaceae family); structure as described in the original literature.
Pulsatilloside E (Chinensioside B) is a triterpenoidal saponin isolated from the roots of Pulsatilla chinensis (Ranunculaceae). It is a 28-O-β-D-glucopyranosyl ester that has neuroprotective effects. The compound can be used for content determination, identification, and pharmacological experiments. It is a research-grade natural product with potential applications in neurological research. It is not approved for clinical use. |
| Molecular Formula |
C65H106O31
|
|---|---|
| Molecular Weight |
1383.52
|
| Exact Mass |
1382.671
|
| CAS # |
366814-43-9
|
| PubChem CID |
10909416
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.53±0.1 g/cm3
|
| Melting Point |
205-208 ºC
|
| Index of Refraction |
1.645
|
| LogP |
2.15
|
| Hydrogen Bond Donor Count |
18
|
| Hydrogen Bond Acceptor Count |
31
|
| Rotatable Bond Count |
18
|
| Heavy Atom Count |
96
|
| Complexity |
2670
|
| Defined Atom Stereocenter Count |
40
|
| SMILES |
O(C1C(C(C(CO1)OC1C(C(C(C(CO)O1)O)O)O)O)OC1C(C(C(C(C)O1)O)O)O)C1CCC2(C)C(C1(C)CO)CCC1(C)C2CCC2C3C(C(=C)C)CCC3(C(=O)OC3C(C(C(C(COC4C(C(C(C(CO)O4)OC4C(C(C(C(C)O4)O)O)O)O)O)O3)O)O)O)CCC12C
|
| InChi Key |
WKNXZHOQPHRDKT-RUGHYGOFSA-N
|
| InChi Code |
InChI=1S/C65H106O31/c1-24(2)27-11-16-65(60(84)96-58-50(82)45(77)40(72)31(91-58)21-85-54-51(83)46(78)52(30(20-67)90-54)94-55-47(79)42(74)37(69)25(3)87-55)18-17-63(7)28(36(27)65)9-10-34-61(5)14-13-35(62(6,23-68)33(61)12-15-64(34,63)8)93-59-53(95-56-48(80)43(75)38(70)26(4)88-56)41(73)32(22-86-59)92-57-49(81)44(76)39(71)29(19-66)89-57/h25-59,66-83H,1,9-23H2,2-8H3/t25-,26-,27-,28+,29+,30+,31+,32-,33+,34+,35-,36+,37-,38-,39+,40+,41-,42+,43+,44-,45-,46+,47+,48+,49+,50+,51+,52+,53+,54+,55-,56-,57-,58-,59-,61-,62-,63+,64+,65-/m0/s1
|
| Chemical Name |
[(2S,3R,4S,5S,6R)-6-[[(2R,3R,4R,5S,6R)-3,4-dihydroxy-6-(hydroxymethyl)-5-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxymethyl]-3,4,5-trihydroxyoxan-2-yl] (1R,3aS,5aR,5bR,7aR,8R,9S,11aR,11bR,13aR,13bR)-8-(hydroxymethyl)-9-[(2S,3R,4S,5S)-4-hydroxy-5-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5a,5b,8,11a-tetramethyl-1-prop-1-en-2-yl-1,2,3,4,5,6,7,7a,9,10,11,11b,12,13,13a,13b-hexadecahydrocyclopenta[a]chrysene-3a-carboxylate
|
| Synonyms |
Chinensioside B; Pulsatilloside E
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.7228 mL | 3.6140 mL | 7.2279 mL | |
| 5 mM | 0.1446 mL | 0.7228 mL | 1.4456 mL | |
| 10 mM | 0.0723 mL | 0.3614 mL | 0.7228 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
